Pivast®

The Hidden gem

Pivastalo Finding it’s Place in therapy

Pivastalo
The Hidden Gem

Differentiation in Pharmacological Action

Pleiotropic effect

Prevention of major CV events

Lower Drop out rate

Patient adherence

Pivastalo®

A distinctive lipid lowering drug

Pivastalo

The Hidden Gem

Pivastalo is characterized by a cyclopropyl moiety that results in Superior Clinically efficacy and Safety profile.



The Lowest Statin Dose *1

Providing inhibition of cholesterol synthesis and increased lipoprotein lipase expression

The Highest Bioavailability *2

Pivastalo has a higher bioavailability (60%-80%) than any other statin

Minimal drug–drug and drug–food interactions *2

Metabolism by CYP2C9 and not metabolized by CYP3A4

Pivastalo
Effective lipid lowering drug

Pivastal
The Hidden Gem

Effective, first-line therapy that offers an alternative, simple treatment regimen in the long-term care of primary hypercholesterolemia and combined dyslipidemia.





Dragos Budinski, Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemia *Clin. Lipidol.* (2009)

Pivastalo Neutral effect on Glycemic Control

Pivastal
The Hidden Gem



The cumulative incidence of (New Onset of Diabetes Mellitus)NODM

was significantly lower in Pivastalo group Compared with the atorvastatin and rosuva





John Jp Kastelein, Pitavastatin: an overview of the LIVES study *Clin. Lipidol.* (2012)

JahYeonChoi, Effect of Pitavastatin Compared with Atorvastatin and Rosuvastatinon New-Onset Diabetes Mellitus in Patients With Acute Myocardial Infarction, Am J Cardiol 2018

Pivastalo
Cardio-Protective Profile

Pivastalo
The Hidden Gem

"The mediated High-Density lipoprotein (HDL) elevation with Pivastalo slow the formation of atherosclerotic plaques and reduce the residual Cardiovascular



John Jp Kastelein, Pitavastatin: an overview of the LIVES study *Clin. Lipidol.* (2012)

Luis Masana, Pitavastatin in cardio metabolic disease: therapeutic profile Masana Cardiovascular Diabetology 2013

Pivastalo Lower Drop Rate

Pivastal
The Hidden Gem

“Pivastalo has the lowest incidence of Adverse Reports“

Table 1: Adverse Reactions* Reported by ≥2% of Patients Treated with Pitavastatin and greater than Placebo in Short-term Controlled Studies

Adverse Reactions*	Placebo (N=208)	Pitavastatin 1 mg (N=309)	Pitavastatin 2 mg (N=951)	Pitavastatin 4 mg (N=1540)
Back Pain	2.9%	3.9%	1.8%	1.4%
Constipation	1.9%	3.6%	1.5%	2.2%
Diarrhea	1.9%	2.6%	1.5%	1.9%
Myalgia	1.4%	1.9%	2.8%	3.1%
Pain In Extremity	1.9%	2.3%	0.6%	0.9%

In controlled clinical studies and the open-label extension, the discontinuation rates due to adverse events were 3.9%, 3.3% and 3.7% for the 1 mg, 2 mg, and 4 mg doses of Pitavastatin respectively.

Pivast®

The Hidden Thing You Sell